Nerve growth factor as a vaccine adjuvant

Details Nerve growth factor as a vaccine adjuvant Nerve growth factor as a vaccine adjuvant

A - Human Necessities

61

K

A61K 39/00 (2006.01) A61K 39/09 (2006.01) A61K 39/102 (2006.01) A61K 39/13 (2006.01) A61K 39/145 (2006.01) A61K 39/25 (2006.01) A61K 39/275 (2006.01) A61K 39/29 (2006.01) A61K 39/39 (2006.01)

Patent

CA 2289040

A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodeficient animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of Nerve Growth Factor (NGF) is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine.

La présente invention concerne un procédé de vaccination selon lequel on utilise une combinaison pharmaceutique qui permet de renforcer l'efficacité du vaccin. Ledit procédé fait appel à un vaccin déclenchant une réaction immunitaire capable de stimuler, chez un animal immunodéficient, la production d'anticorps dirigés contre un agent provoquant des maladies étranger à l'animal. On administre, comme adjuvant, une quantité de facteur de croissance nerveuse (FCN) qui renforce l'efficacité du vaccin en stimulant la production et l'affinité des anticorps de l'animal en réponse au vaccin.

Affiliated with

Also associated with

Rating

Nerve growth factor as a vaccine adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nerve growth factor as a vaccine adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nerve growth factor as a vaccine adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1726090